mortality/aging
• tamoxifen- and beta-naphthoflavone-induced mice median survival is 99 days compared to 405 days for wild-type Pten homozygotes or 409 days for wild-type Apc homozygotes
|
digestive/alimentary system
• 95% of tamoxifen- and beta-naphthoflavone-induced mice exhibit large, flattened, ulcerated lesions in the small intestine unlike control mice homozygous for either a wild-type Pten or Apc allele
|
• tamoxifen- and beta-naphthoflavone-induced mice develop invasive adenocarcinomas in the small intestines with luminal ulceration, and both acute and chronic inflammation compared to control mice that exhibit begnin neoplasms
• invasion and destruction of the small intestinal wall and peritoneal serosa results in localized peritonitis in tamoxifen- and beta-naphthoflavone-induced mice
|
• invasion and destruction of the small intestinal wall and peritoneal serosa by adenocarcinomas results in localized peritonitis in tamoxifen- and beta-naphthoflavone-induced mice
|
neoplasm
• tamoxifen- and beta-naphthoflavone-induced mice develop invasive adenocarcinomas in the small intestines with luminal ulceration, and both acute and chronic inflammation compared to control mice that exhibit begnin neoplasms
• invasion and destruction of the small intestinal wall and peritoneal serosa results in localized peritonitis in tamoxifen- and beta-naphthoflavone-induced mice
|
immune system
• invasion and destruction of the small intestinal wall and peritoneal serosa by adenocarcinomas results in localized peritonitis in tamoxifen- and beta-naphthoflavone-induced mice
|